Five-year data supported the long-term safety and effectiveness of transvenous phrenic nerve stimulation (TPNS) for central sleep apnea (CSA), investigators said.

CSA severity decreased in patients after Remede device implantation and stayed that way out to 5 years, according to a group led by Maria Rosa Costanzo, MD, of Advocate Heart Institute in Chicago:

• More than half of patients maintained improvement of apnea hypopnea index (AHI) at both 1 year and 5 years
• Central apnea index remained under 1 event per hour at 1 year and 5 years alike versus a baseline of roughly 23 events per hour
• Over half of patients achieved sustained improvement in arousals through 5 years
• Arousals totaled 19 per hour at both 1 year and 5 years, down from a baseline of roughly 39 arousals per hour
• Daytime sleepiness scores on the Epworth scale stayed at a median 6 points at 1 and 5 years,